Europe miRNA Sequencing and Assay Market Growth Opportunities and Forecast by 2027

Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Library Preparation and Consumables), Technology (Sequencing by Synthesis, Nanopore, and Ion Semiconductor Sequencing), and End User (Research Institute, Academia, and CRO)

Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027
  • Status : Published
  • Report Code : TIPRE00022148
  • Category : Life Sciences
  • No. of Pages : 120
  • Available Report Formats : pdf-format excel-format
  • Last update date : May 07, 2021
Europe miRNA Sequencing and Assay Market Growth Opportunities and Forecast by 2027
Report Date: May 07, 2021   |   Report Code: TIPRE00022148 Email: sales@theinsightpartners.com

2019 Market Size

US$ 62.30 Mn

Base year value

2027 Forecast

US$ 144.87 Mn

Projected by 2027

CAGR 2020-2027

11.3 %

Growth rate

Addressable Market

US$ 831.37 Mn

(2020-2027)

The Europe miRNA sequencing and assay market is expected to reach US$ 144.87 million by 2027 from US$ 62.30 million in 2019; it is estimated to grow at a CAGR of 11.3% from 2020 to 2027.



The widening application range of microRNAs and rise in funding for genomics research. However, challenges associated with the delivery, efficacy, and specificity of miRNA-based therapeutics hinder the market growth.

MicroRNAs (miRNAs) are noncoding RNAs that are partially complementary to messenger RNA (mRNA). They are known to downregulate the expression, which makes them vital regulators of important cellular functions. Being involved in the process of differentiation, they act as markers in cell type identification. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, extensive research is being conducted to identify new miRNAs. Furthermore, new discoveries regarding the role of miRNAs in disease development have made them a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Europe.

The COVID-19 pandemic has been having some serious effects on European countries. The miRNA sequencing and assay market in the region witnessed shortfall at the beginning of the pandemic crisis due to disruptions in supply chain and lowered demands due to lockdown imposed by many European countries. However, later, the demand for the miRNA sequencing and assay products increased drastically with supportive government initiatives. Many private research organizations have expanded their research teams and projects to accelerate studies related to SARS-CoV-2. For instance, QIAGEN, Germany, a pioneer in next-generation sequencing (NGS), has expanded its integrated coronavirus next-generation sequencing platforms and software solutions to accelerate COVID-19 research. Hence, the COVID-19 pandemic has been supporting the Europe miRNA sequencing and assay market growth.

Europe miRNA sequencing and assay market

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Europe miRNA Sequencing and Assay Market Segmentation

By Product

  • Library Preparation
  • Consumables

By Technology

  • Sequencing by Synthesis
  • Nanopore
  • Ion Semiconductor Sequencing

By End User

  • Research Institute
  • Academia
  • CRO

By Country

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

Company Profiles

  • Illumina, Inc
  • THERMO FISHER SCIENTIFIC INC.
  • QIAGEN
  • Perkin Elmer, Inc.
  • Takara Bio Inc.
  • New England Biolabs
  • Norgen Biotek Corp
  • TriLink BioTechnologies Inc.
  • Lexogen GmbH
  • Oxford Nanopore Technologies

Europe miRNA Sequencing and Assay Report Scope

Report Attribute Details
Market size in 2019 US$ 62.30 Million
Market Size by 2027 US$ 144.87 Million
CAGR (2020 - 2027) 11.3%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Product
  • Library Preparation and Consumables
By Technology
  • Sequencing Synthesis
  • Nanopore
  • Ion Semiconductor Sequencing
By End User
  • Research Institute
  • Academia
  • CRO
Regions and Countries Covered Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Market leaders and key company profiles
  • Illumina, Inc
  • THERMO FISHER SCIENTIFIC INC.
  • QIAGEN
  • Perkin Elmer, Inc.
  • Takara Bio Inc.
  • New England Biolabs
  • Norgen Biotek Corp
  • TriLink BioTechnologies Inc.
  • Lexogen GmbH
  • Oxford Nanopore Technologies
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA